SURPASS-ET: phase III study of ropeginterferon alfa-2b versus ...
High-risk essential thrombocythemia (ET) patients face limited treatment options. Hydroxyurea is first-line but some resist or can't tolerate it. Anagrelide is second-line but may increase disease transformation risk. Ropeginterferon alfa-2b, with a good safety profile, is being compared to anagrelide in the SURPASS-ET trial for ET patients resistant to or intolerant of hydroxyurea.
Related Clinical Trials
Reference News
High-risk essential thrombocythemia (ET) patients face limited treatment options. Hydroxyurea is first-line but some resist or can't tolerate it. Anagrelide is second-line but may increase disease transformation risk. Ropeginterferon alfa-2b, with a good safety profile, is being compared to anagrelide in the SURPASS-ET trial for ET patients resistant to or intolerant of hydroxyurea.